Pharmacokinetics of 2'-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat. 1987

J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
Department of Pharmacology, University of Manitoba, Faculty of Medicine, Winnipeg, Canada.

The distribution of the potent inhibitor of adenosine deaminase (ADA), 2'-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. The accumulation of [3H]DCF in brain was maximal 2 hr after intraperitoneal injection and elimination was best described by a two compartment model having t1/2 phases of about 1-5 hr and 50 hr. The activity of ADA in gut exhibited dose-related inhibition at 1.9, 3.7 and 18.6 mumol/kg (i.p.) and returned to normal by 16 days. In brain, ADA was inhibited by about 95% at all three of these doses of DCF 2 hr after injection and activity returned to control levels by 30 days with the two smaller doses, but remained at 66% of control levels at 50 days with 18.6 mumol/kg. The t1/2 of the recovery of the activity of ADA in both brain and gut was found to be dose-dependent. The failure of the activity of ADA in brain to recover after treatment with 18.6 mumol/kg suggests either long-term down-regulation of the expression of ADA or irreversible damage to ADA-containing neurons.

UI MeSH Term Description Entries
D007421 Intestine, Small The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM. Small Intestine,Intestines, Small,Small Intestines
D008297 Male Males
D009700 Nucleoside Deaminases Catalyze the hydrolysis of nucleosides with the elimination of ammonia. Deaminases, Nucleoside
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003070 Coformycin A ribonucleoside antibiotic synergist and adenosine deaminase inhibitor isolated from Nocardia interforma and Streptomyces kaniharaensis. It is proposed as an antineoplastic synergist and immunosuppressant.
D000243 Adenosine Deaminase An enzyme that catalyzes the hydrolysis of ADENOSINE to INOSINE with the elimination of AMMONIA. Adenosine Aminohydrolase,Aminohydrolase, Adenosine,Deaminase, Adenosine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012263 Ribonucleosides Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed)
D015649 Pentostatin A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. 2'-Deoxycoformycin,CI-825,Co-Vidarabine,Deoxycoformycin,Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (R)-,NSC-218321,Nipent,2' Deoxycoformycin,CI 825,CI825,NSC 218321,NSC218321

Related Publications

J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
January 1980, Cancer chemotherapy and pharmacology,
J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
January 1979, Advances in experimental medicine and biology,
J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
April 1980, Biochemical pharmacology,
J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
October 1981, Clinical immunology and immunopathology,
J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
January 1979, Advances in experimental medicine and biology,
J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
January 2007, In vivo (Athens, Greece),
J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
January 1977, Pharmacology,
J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
July 1980, Lancet (London, England),
J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
February 1987, Immunopharmacology,
J D Geiger, and J L Lewis, and C J MacIntyre, and J I Nagy
September 1982, Cellular immunology,
Copied contents to your clipboard!